Expert Interview
Delving into Alnylam Pharmaceuticals, Inc.'s Zilebesiran (ALN-AGT) for the Treatment of Hypertension: Insights from the KARDIA-2 Phase 2 Study
Ticker(s): ALNYInstitution: Renown Medical Center Institute for Heart and Vascular Health (Nevada)
- Medical Director of Vascular Medicine and Anticoagulation Services at the Renown Medical Center Institute for Heart and Vascular Health; served as Vice President of the Board of the American Society of Hypertension (ASH).
- Manages hundreds of patients with hypertension, about ~40 patients with lp(a) >150 mg/dl, and <150 patients with SHTG
- Clinical Interests include management of hypertension, dyslipidemia, anticoagulation, vascular disease, and heart disease and stroke prevention.
- Principal investigator on numerous clinical trials, most recently focused in the field of device therapy for hypertension. Research focused on diagnosis and management of renovascular disease and exploring novel means of overcoming barriers to hypertension and dyslipidemia control.
The KARDIA-2 study demonstrated clinically significant additive reductions in ambulatory and office systolic blood pressure with the addition of zilebesiran to standard antihypertensive therapy. How do these findings impact the current approach to managing inadequately controlled hypertension?
Considering the substantial reductions in systolic blood pressure observed across multiple study cohorts, how do you envision the integration of zilebesiran into existing hypertension treatment algorithms?
Added By: slingshot_insightsZilebesiran demonstrated an encouraging safety and tolerability profile in the KARDIA-2 study. What are your key takeaways regarding the safety profile of zilebesiran, particularly in terms of hypotension, orthostatic hypotension, and kidney function?
Added By: slingshot_insights While the KARDIA-2 study demonstrated significant reductions in blood pressure at three and six months, what are the key considerations regarding the long-term efficacy of zilebesiran, especially in sustaining blood pressure control over extended periods?
Zilebesiran offers the potential for biannual dosing, which could address challenges related to medication adherence and therapeutic inertia in hypertension management. How transformative could this dosing regimen be for patients with hypertension?
With the potential of achieving durable tonic blood pressure control, how might Zilebesiran address the current unmet needs in the hypertension patient population?
Added By: slingshot_insightsZilebesiran is being co-developed and co-commercialized by Alnylam and Roche. How do you foresee this collaboration shaping the future development and availability of zilebesiran for patients with hypertension?
Considering the robust efficacy and encouraging safety profile of zilebesiran, how do you anticipate its integration into clinical practice and its potential to improve cardiovascular outcomes for patients with hypertension?
Added By: slingshot_insightsGiven the sustained blood pressure reductions observed with Zilebesiran, how might this impact the long-term cardiovascular health of patients with hypertension?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
